In patients with bilateral primary hyperaldosteronism (PA) and those with unilateral PA who are unwilling or unable to undergo adrenalectomy an increase in plasma renin activity (PRA) provided by mineralocorticoid receptor antagonists (MRAs) therapy reflects sufficient antagonism for elevated aldosterone. Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) have cardiovascular, renal protective properties and some clinical data have shown an increase in PRA levels with SGLT2-i. Here, we present our experience of using SGLT2-i in PA patients with suppressed PRA despite 100 mg/day spironolactone therapy.

中文翻译：

---

解决方案并不简单；钠-葡萄糖协同转运蛋白 2 抑制剂在 Conn 综合征中的应用。

在双侧原发性醛固酮增多症 (PA) 患者和不愿意或无法接受肾上腺切除术的单侧 PA 患者中，盐皮质激素受体拮抗剂 (MRA) 治疗带来的血浆肾素活性 (PRA) 增加反映了对醛固酮升高的足够拮抗作用。钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2-i) 具有心血管、肾脏保护特性，一些临床数据显示 SGLT2-i 可以提高 PRA 水平。在此，我们介绍了在接受 100 毫克/天螺内酯治疗但 PRA 仍受到抑制的 PA 患者中使用 SGLT2-i 的经验。